Mirum Pharmaceuticals Reports Strong 2025 Results, Issues Robust 2026 Sales Guidance, and Highlights Key Pipeline Catalysts

summarizeSummary

Mirum Pharmaceuticals reported strong full-year 2025 financial results, including significant product sales growth, and provided optimistic 2026 sales guidance alongside a robust pipeline update with multiple key data readouts expected.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported total net product sales of $521.3 million for the full year 2025, a substantial increase from $336.4 million in 2024. LIVMARLI sales grew 69% year-over-year to $360.0 million.

• Robust 2026 Sales Guidance

  Issued 2026 global net product sales guidance of $630 million to $650 million, indicating continued strong commercial growth.

• Key Pipeline Catalysts Expected in 2026

  Anticipates multiple late-stage clinical trial readouts, including Volixibat VISTAS study (PSC) topline data in Q2 2026, LIVMARLI EXPAND study topline data in Q4 2026, and Brelovitug AZURE-1 and AZURE-4 studies (HDV) topline data in H2 2026.

• Improved Financial Position

  Reduced net loss to $23.363 million for 2025 from $87.942 million in 2024, and increased unrestricted cash, cash equivalents, and investments to $391.4 million as of December 31, 2025.

auto_awesomeAnalysis

Mirum Pharmaceuticals delivered strong financial results for 2025, significantly increasing net product sales and reducing its net loss. The company's 2026 sales guidance of $630 million to $650 million indicates continued robust growth, building on the momentum from its approved products like LIVMARLI. Furthermore, the detailed pipeline update, with multiple late-stage clinical trial readouts expected throughout 2026, provides significant catalysts for future value creation in a catalyst-rich period for the company. The improved cash position also strengthens its financial flexibility.